CA 50, Method: RIA by DIASource (Serum (s))
| Specimens: | 100 µl Serum (s) |
| Info: | Note: Tumor marker analysis results which have been obtained by different analysis methods (tests) e. g. from different manufacturers may be not comparable. Thus, longitudinal control of a tumor marker should always be done with the same testkit. |
| Preanalytics/Notes: | Note: Tumor marker analysis results which have been obtained by different analysis methods (tests) e. g. from different manufacturers may be not comparable. Thus, longitudinal control of a tumor marker should always be done with the same testkit. |
| Method: | RIA |
| Dimension: | U/ml |
| Set-up: | Mon Tue Wed Thu Fri Sat Sun |
| Duration: | 5 days |
| Indication/Significance: | Aftercare/therapy control of carcinomas of the gastrointestinal tract, endometrium or urine bladder |
| Interpretation: |
Benigns diseases can more… Benigns diseases can also lead to CA 50 increases (acut or chronic pancreatitis, ulcerating colitis, Crohn´s disease, liver cirrhosis, hepatitis, cholelithiasis, pneumonia). |
Reference range / valuation (openclose)
| both sex | ||
|---|---|---|
| < 23,5 U/ml | ||
initial letter
Abrechnung GOÄ
Die Kosten werden für den i. d. R. genutzten 1,15-fachen GOÄ-Satz dargestellt. Wird die Untersuchung nicht in Ihrem regionalen Labor durchgeführt, erfolgt die Analyse in dem Labor, das im Leistungsverzeichnis genannt ist. In diesem Fall gilt der dort für die Untersuchung angegebene Preis.